The ComplyAdvantage alternative for firms that want their own screening brain.
ComplyAdvantage is a good screening product — sanctions, PEPs, adverse media, ongoing monitoring, all in one API. It is also a vendor that owns the risk taxonomy your firm signs off against. In 2026, serious firms are keeping ComplyAdvantage (or Refinitiv / Dow Jones) as a data source and building the risk brain themselves.
1 — What ComplyAdvantage actually is
ComplyAdvantage is a screening and monitoring platform covering sanctions, watchlists, PEPs, RCAs, adverse media, customer screening, ongoing monitoring and company screening. It is used across banks, fintechs, payments, crypto and regulated marketplaces as either primary or secondary screening.
Public pricing for the entry "Starter Plan" is disclosed on their website — from $99 / month for 100 monitored entities, scaling to 2,000 monitored entities. Enterprise pricing for larger firms is negotiated per client and is not public. The API is well-documented, the coverage is strong, and integration is fast — that is much of the reason for the product's popularity with fintechs.
The real question in 2026 is not which screening vendor to use. It is who owns the resulting risk decisions — a vendor's risk taxonomy, or your firm's own model of what "unacceptable risk" looks like for your specific customer base.
2 — What ComplyAdvantage costs you
ComplyAdvantage publishes headline Starter Plan pricing: from $99 per month for 100 monitored entities, up to 2,000 monitored entities on the Starter tier. Enterprise, Payment Screening and Agentic tiers are quoted per client and are not public.
For a mid-sized fintech or bank, the loaded cost of ComplyAdvantage plus the wrapper it needs typically looks like this.
| Line item | Order-of-magnitude cost | Note |
|---|---|---|
| ComplyAdvantage Starter Plan | From $99 / mo for 100 monitored entities | Public pricing; scales to 2,000 entities. |
| ComplyAdvantage enterprise (Sanctions / PS / Agentic) | Not publicly disclosed | Per-firm, per-volume commercials at scale. |
| Payment Screening (real-time) | Not publicly disclosed | Deployed on AWS Marketplace; enterprise commercials. |
| Alert operations team (screening L1) | £300k – £2m+ / yr | The dominant screening cost line at scale. |
| Secondary data source (Refinitiv WorldCheck, Dow Jones Risk) | £100k – £500k / yr | Serious firms usually run two screening data sources. |
| Integration + case-management wrap | £100k – £300k / yr | In-house or via case-management vendor. |
As with any screening vendor, the licence line is not the dominant cost — the alert operations team is. Reducing false-positive rate on screening (and materially reducing time-to-decision on real hits) is where the money is.
None of that is wasted if it produces a defensible screening posture. What is wasted is spending it and still letting a vendor own the risk taxonomy your compliance team signs off against.
3 — What ComplyAdvantage can't do for your firm
ComplyAdvantage is a good screening product. Five things it structurally does not do for a modern compliance function.
It gives you alerts, not your firm's risk view
ComplyAdvantage flags a name against sanctions, PEP or adverse-media lists. It does not know your firm's specific risk appetite, your product-specific concentration limits, or the two adverse-media stories that actually matter for your customer segment. Firm-specific risk assessment lives in a firm-owned layer.
Adverse-media relevance is generic
The adverse-media stream is high-volume and largely irrelevant to any specific firm. Filtering "which of these 40 stories actually change our view of this customer" needs a firm-specific model trained on the firm's own historical decisions.
The risk taxonomy is the vendor's, not yours
Vendor risk categories are reasonable. They are not necessarily the categories your MLRO signs off against. Owning your own taxonomy — and mapping vendor data into it — is the entire game.
Investigator experience is a case queue, not intelligence
The screening console is fine as a queue. It is not an AI-native cockpit that pre-drafts the customer-risk narrative, links to related customers across the entity graph and highlights the two facts that resolve the alert. That layer has to be firm-owned.
Every improvement is a ComplyAdvantage release
New capability arrives on the vendor's cycle. Fine for a screening data source. The wrong dependency for the risk-decision layer that determines your firm's onboarding conversion, ongoing-monitoring economics and regulator posture.
4 — Why 'your own version' is viable in 2026
The right frame is not "replace ComplyAdvantage." A serious firm typically runs two screening data sources (ComplyAdvantage plus Refinitiv WorldCheck or Dow Jones Risk) — both stay. The right frame is: build a firm-owned risk decision layer that ingests every screening hit from every vendor and applies the firm's own model.
Every screening alert, KYC document, historical decision and manual override streams into a firm-owned warehouse. On top, a firm-specific model triages hits against the firm's own taxonomy, drafts the customer-risk narrative, links to related customers across the entity graph, and — for adverse-media — filters to the small subset that actually changes the firm's view.
Screening vendors become interchangeable data sources. The risk view — the number your MLRO and your regulator actually care about — is firm-owned and compounds every quarter.
5 — Reference architecture
Firm-owned risk decision layer above ComplyAdvantage and other screening vendors
Every screening vendor stays as a data source. ComplyAdvantage continues to run sanctions, PEP, adverse-media and monitoring. Secondary sources continue in parallel.
Every hit, every KYC file and every historical decision streams into a firm-owned data spine. The intelligence layer triages hits against the firm's own risk taxonomy, drafts the customer-risk narrative, filters adverse media to genuine relevance, and links across the entity graph.
The compliance analyst works in a firm-owned cockpit (with the vendor console still available). Every decision, every AI proposal and every human sign-off feeds back into the firm's decision history and training data.
6 — Build vs. rent: 3-year TCO
A three-year illustrative comparison for a mid-sized bank / fintech using ComplyAdvantage.
| Dimension | Rent (ComplyAdvantage) | Build (KJ Capital) |
|---|---|---|
| ComplyAdvantage enterprise | Not publicly disclosed; 6-figure annual typical at scale | Unchanged |
| Secondary screening (Refinitiv / Dow Jones) | £100k – £500k / yr | Unchanged |
| Screening L1 operations team | £300k – £2m+ / yr | Materially reduced per alert; team retrained onto higher-value work |
| Case-management / wrapper tooling | £100k – £300k / yr | Rationalised into firm-owned cockpit |
| Intelligence layer (LLM infra + evals) | N/A | £250k – £500k / yr |
| Initial build (Yr 1 only) | N/A | £350k – £700k one-off KJ Capital build |
| 3-year total (illustrative) | Rising ops cost with monitored-entity growth | Alert-cost / analyst-cost breaks the escalator; owned proprietary layer |
The break-even is usually inside 18 months on realistic adverse-media filtering and narrative-drafting productivity. The strategic value is bigger: the firm owns the model that decides which screening hits matter.
7 — The three honest risks of building your own
"Our regulator recognises ComplyAdvantage."
How we solve it —They continue to. ComplyAdvantage remains a screening data source and its console remains available. The intelligence layer strengthens the audit trail — every decision, every human sign-off is logged with provenance in the firm-owned system.
"We can't have AI making sanctions decisions."
How we solve it —It doesn't. Every triage, every narrative and every decision is a proposal with explicit human sign-off. The system exists to make analysts faster and more accurate — not to replace their judgment on regulated decisions.
"We don't have an in-house AI team."
How we solve it —You don't need one on day one. Build ships the first system in 6–12 weeks. Operator runs it in production while your team takes ownership.
8 — The CTA ladder
ComplyAdvantage is a good screening product. It is not, and does not need to be, your firm's risk-decision brain. That brain has to be firm-owned to compound and to earn regulator trust in the long run.
The right sequence is Readiness → Audit → Blueprint. Two weeks with our team and you have a scoped plan you can put in front of your MLRO.
Free Readiness Score
5 minutes. Honest score of whether your firm is in a position to build.
AI Diagnostic — £15k / 2 weeks
Founder-led. Map the specific systems where you'd get compounding return.
Blueprint conversation
30-minute call with Kasim to scope the Build.
Five questions we get asked most.
Do we need to leave ComplyAdvantage?+
No. ComplyAdvantage stays as a screening data source and its console remains available. The intelligence layer is additive and ingests hits from every screening vendor the firm uses.
What does ComplyAdvantage actually cost?+
ComplyAdvantage publishes Starter Plan pricing (from $99 / month for 100 entities, up to 2,000 entities). Enterprise and Agentic tiers are quoted per firm. The dominant cost line for most firms is the screening operations team, not the licence.
How much can this reduce false positives on adverse media?+
Realistic firm-specific model results are typically a 60–90% reduction in adverse-media noise reaching an analyst, without meaningfully changing recall on genuinely material events. Real numbers depend heavily on firm data quality and starting posture.
Can this work with Refinitiv WorldCheck or Dow Jones Risk instead?+
Yes. The intelligence layer is vendor-agnostic and ingests hits from any screening data source. The firm-owned risk taxonomy and decision model are the same.
How long until the first system is live?+
The Diagnostic is 2 weeks. The first Build is 6–12 weeks and typically ships adverse-media relevance filtering + customer-risk narrative on a defined customer segment, with Operator running it in production.